767 results about "Greek letter beta" patented technology

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.

Imaging apparatus, is provided, comprising a first device, for obtaining a first image, by a first modality, selected from the group consisting of SPECT, PET, CT, an extracorporeal gamma scan, an extracorporeal beta scan, x-rays, an intracorporeal gamma scan, an intracorporeal beta scan, an intravascular gamma scan, an intravascular beta scan, and a combination thereof, and a second device, for obtaining a second, structural image, by a second modality, selected from the group consisting of a three-dimensional ultrasound, an MRI operative by an internal magnetic field, an extracorporeal ultrasound, an extracorporeal MRI operative by an external magnetic field, an intracorporeal ultrasound, an intracorporeal MRI operative by an external magnetic field, an intravascular ultrasound, and a combination thereof, and wherein the apparatus further includes a computerized system, configured to construct an attenuation map, for the first image, based on the second, structural image. Additionally, the computerized system is configured to display an attenuation-corrected first image as well as a superposition of the attenuation-corrected first image and the second, structural image. Furthermore, the apparatus is operative to guide an in-vivo instrument based on the superposition.

The present invention provides a compound of formula I and the use thereof for the therapeutic treatment, prevention or amelioration of a disease or disorder characterized by elevated β-amyloid deposits or β-amyloid levels in a patient.

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.

The present invention provides a 2-amino-5-[4-(difluoromethoxy)phenyl]-5-phenylimidazolone compound of formula I The present invention also provides methods for the use thereof to inhibit β-secretase (BACE) and treat β-amyloid deposits and neurofibrillary tangles.

Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures.

The present invention provides a 2-amino-5-cycloalkyl-hydantoin compound of formula I The present invention also provides methods and compositions for the inhibition of β-secretase (BACE) and the treatment of β-amyloid deposits and neurofibrillary tangles.

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include antibodies, e.g., humanized antibodies.

Disclosed herein are titanium-tungsten alloys and composites wherein the tungsten comprises 0.5% to 40% by weight of the alloy. Also disclosed is a method of making such alloys and composites using powders of tungsten less then 3 μm in size, such as 1 μm or less. Also disclosed is a method of making the titanium alloy by powder metallurgy, and products made from such alloys or billets that may be cast, forged, or extruded. These methods of production can be used to make titanium alloys comprising other slow-diffusing beta stabilizers, such as but not limited to V, Nb, Mo, and Ta.

The present invention relates to a method for preparing a peptide having a stable, internally constrained alpha-helical, beta-sheet / beta-turn, 310-helical, or pi-helical region and a method of stabilizing an alpha-helical, beta-sheet / beta-turn, 310-helical, or pi-helical region within a peptide structure. The resulting peptides and methods of using them are also disclosed.

The invention relates to a process for the production of a molded porous ceramic article containing β-SiC, which process comprises the following steps: the preparation of a molded article containing silicon and carbon and the subsequent pyrolysis and siliconization of the article containing silicon and carbon to form SiC. The invention further relates to a molded porous ceramic article containing SiC which has been produced from a molded article containing silicon and carbon.

A thermoplastic ionomer blend or alloy exhibiting advantageous properties upon molding or extrusion and / or thermoforming, consisting essentially of the following components:A. about 15 to 85 parts by weight of a thermoplastic copolymer containing about 91 to 80 weight percent of alpha-olefin units and about 9 to 20 weight percent of alpha, beta-ethylenically unsaturated carboxylic acid units said carboxylic acid units being about 20 to 90 percent neutralized with metal ions, preferably zinc,B. about 10 to 80 parts by weight of a rubber, preferably a thermoplastic elastomer selected from the group consisting of (a) crosslinked ethylene-propylene-diene copolymers and equivalent polyolefin copolymers such as ethylene-butene, hexene, or octene, (b) acrylonitrile-butadiene copolymers, (c) styrene-butadiene copolymers, and (d) styrene acrylonitrile graft-crosslinked butadiene rubbers, andC. about 5 to 40 parts by weight of a thermoplastic polymer selected from the group consisting of polyethylene and polypropylene copolymers and homopolymers, the total number of parts being 100,and molded or extruded and / or thermoformed products produced from the same.

The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.

A process for making a relatively low molecular weight, mid-range vinylidene content PIB polymer product comprising a liquid phase polymerization process conducted in a loop reactor at a temperature of at least 60° F. using a BF3 / methanol catalyst complex and a contact time of no more than 4 minutes. At least about 90% of the PIB molecules present in the product comprise alpha or beta position isomers. The vinylidene (alpha) isomer content of the product may range from 20% to 70% thereof, and the content of tetra-substituted internal double bonds is very low, advantageously no more than about 10%, preferably less than about 5% and ideally less than about 1-2%.

An information need can be modeled by a binary classifier such as support vector machine (SVM). SVMs can exhibit very conservative precision oriented behavior when modeling information needs. This conservative behavior can be overcome by adjusting the position of the hyperplane, the geometric representation of a SVM. The present invention describes a couple of automatic techniques for adjusting the position of an SVM model based upon a beta-gamma thresholding procedure, cross fold validation and retrofitting. This adjustment technique can also be applied to other types of learning strategies.

The present invention is a new stable extended release drug composition particularly suitable for use as a beta-adrenoreceptor antagonist agent. The present invention is specifically a drug composition comprising a pharmaceutical, a methacrylic acid copolymer and a matrix forming agent, and a method for manufacturing same. When applied to highly soluble drugs like metoprolol succinate, the resulting drug composition is characterized by an extended-release profile.

This invention relates to compounds, compositions, and methods useful for modulating transforming growth factor beta (TGF-beta) and / or transforming growth factor beta receptor (TGF-betaR) gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of TGF-beta and / or TGF-betaR gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of TGF-beta and / or TGF-betaR genes.

The present invention relates to compositions of and methods for producing timed or retarded release formulations that contain glucosamine sulfate, beta-(1,4)-2-amino-2-deoxy-D-glucose, and chondroitin, (C14H19NO14SNa2)n; N-acetylchondrosanine (2-acetamide-2-deoxi-D-galactopiranose) and D-gluoronic acid copolymer and / or their dietary and nutraceutically acceptable salts of the same and / or hydrates of the active substance that provide a timed release formulation of the active substance.

The present invention relates to inhibitors of 11-β hydroxyl steroid dehydrogenase type 1 and pharmaceutical compositions thereof. The compounds of the invention can be useful in the treatment of various diseases associated with expression or activity of 11-β hydroxyl steroid dehydrogenase type 1.

A process for the fractionation of valuable fractions from cereal brans (e.g. wheat, barley and oat brans, and rice polish) is described. In particular, this invention describes a two step process, in which the said bran is first subjected to a combination of enzymatic treatment and wet milling, followed by sequential centrifugation and ultrafiltration, which aims at physically separating the main bran factions, i.e. insoluble phase (pericarp and aleurone layer), germ-rich fraction, residual endosperm fraction and soluble sugars. A second step consists of fractionating cereal brans substantially free of soluble compounds, hence insoluble phase from the above-mentioned first step, by enzymatic treatment with xylanases and / or beta-glucanase and wet milling, followed by sequential centrifugation and ultrafiltration, which aims at physically separating the main fractions, i.e. insoluble phase (remaining cell wall components), protein-rich fraction, soluble hemicellulose and oligosaccharide, and therefore maximizes the extraction rate of valuable cell wall components and aleurone cells from previously cleaned bran.

This invention further relates to a method for preventing or treating diseases or conditions of the oral cavity, throat or nose of warm-blooded animals including humans. More particularly, the invention pertains to a composition and method for spraying essential oils to the oral cavity, throat or nasal mucosa as cyclodextrin inclusion complexes. The spray composition includes a cyclodextrin in an amount of from about 0.1% w / v to about 20% w / v; at least one essential oil in an amount of from about 0.001% w / v to about 5.0% w / v; an effective amount of an antimicrobial preservative composition; and water. The composition may further comprise an alcohol co-solvent, a thickening agent, a sweetener, an antitussive, an anticholinergic, a decongestant, an antihistamine, an astringent, an anti-inflammatory steroid composition, a vitamin, a respiratory stimulant, a mucolytic agent, a bronchodilator, a beta-antagonist, an antidiarrheal agent, or combinations thereof.

Disclosed is a method of making β-polypeptides. The method includes polymerizing β-lactam-containing monomers in the presence of a base initiator and a co-initiator which is not a metal-containing molecule to yield the product β-polypeptides. Specifically disclosed are methods wherein the base initiator is potassium t-butoxide, lithium bis(trimethylsilyl)amide (LiN(TMS)2), potassium bis(trimethyl-silyl)amide, and sodium ethoxide, and the reaction is carried out in a solvent such as chloroform, dichloromethane, dimethylsulfoxide, or tetrahydrofuran.

An efficacious antibacterial and anti-inflammatory oral composition is provided having an active ingredient combination comprising one or more active compounds from an extract of magnolia and an extract of hops. Preferably, the active compounds from magnolia extract comprise honokiol and magnolol, and the active compounds from hops extract comprise hexahydrogenated beta acids. The oral composition can be in the form of a mouth rinse or dentifrice, including toothpaste, gels, powders, confectionaries, lozenges, animal products, and the like. Methods of making and using the oral composition are also provided.

This invention relates to compounds, compositions, and methods useful for modulating TGF-beta and / or TGF-betaR gene expression using short interfering nucleic acid (siNA) molecules. This invention also relates to compounds, compositions, and methods useful for modulating the expression and activity of other genes involved in pathways of TGF-beta and / or TGF-betaR gene expression and / or activity by RNA interference (RNAi) using small nucleic acid molecules. In particular, the instant invention features small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA), double-stranded RNA (dsRNA), micro-RNA (miRNA), and short hairpin RNA (shRNA) molecules and methods used to modulate the expression of TGF-beta and / or TGF-betaR genes. Such small nucleic acid molecules are useful, for example, for treating, preventing, inhibiting, or reducing inflammatory, respiratory, autoimmune, and / or proliferative diseases, disorders, conditions, or traits in a cell, subject or organism and any other disease, condition, trait or indication that can respond to the level of TGF-beta and / or TGF-betaR in a cell or tissue; or alternately in providing long term hematopeitic reconstitution in a subject or organism.

The invention relates to a core shell capsule containing in the core an oil or waxy solid, wherein the oil or waxy solid comprises: (1) 50-100% by weight of a perfume composition, which is a mixture of at least two perfume ingredients-selected from: a) aldehydes, including alpha beta unsaturated aldehydes, which constitute 0-20% by weight of the perfume composition; b) primary or secondary amines constituting 0-10% by weight of the perfume composition; c) perfume ingredients having ClogP>4.0, which constitute 0-25% by weight of the perfume composition; d) perfume ingredients having ClogP>5.0, which constitute 0-20% by weight of the perfume composition; and e) perfume ingredients having ClogP<2.0, which constitute 0-20% by weight of the perfume composition, and (2) 0-50% by weight of benefit agents other than perfume ingredients.

Ligand Drug conjugate compounds comprising a β-glucuronide-based linker and methods of using such compounds are provided.

The invention relates to a liquid, propellant-free pharmaceutical formulation in the form of ready-to-use preparation for administration by nebulisation comprising a water soluble salt of the beta2-agonist 8-hydroxy-5-[1-hydroxy-2-[[2-(4-methoxyphenyl)-1-methylethyl]amino]ethyl]-2(1H)-quinolinone as active ingredient. The active ingredient is chemically stable in the formulation, and said formulation is provided of an adequate shelf-life suitable for commercial distribution, storage and use.

The invention provides improved agents and methods for treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient. Preferred agents include humanized antibodies.

In one aspect, the invention is directed to a concentrate comprising a polypropylene resin and a beta-nucleating agent, wherein the nucleating agent is present in a concentration in the concentrate in a range of from about 0.005% to about 2.0%. In another aspect, the invention is directed to an extruded polypropylene sheet comprising a beta-nucleating agent concentrate in a concentration of between about 0.5% to about 50% by weight of the total polypropylene content. In a further aspect, the invention is directed to a method of manufacture of a beta-nucleating agent / polypropylene concentrate comprising the step of blending a substantially pure beta-nucleating agent with a substantially non-nucleated polypropylene resin to provide a concentration in the concentrate of from about 0.005% to about 2.0%. In yet another aspect, the invention is directed to a film produced by stretching the sheet.